Skip to main content
Premium Trial:

Request an Annual Quote

Mireven Secures Additional Funding

Premium

Australian microRNA drug developer Mireven said last week that it has received an additional A$500,000 ($511,000) from early-stage investment group Medical Research Commercialization Fund, bringing the total investment MRCF has made in the company to A$1.1 million.

According to Mireven, the additional investment is the result of its achievement of undisclosed technical and commercial milestones. The company is developing a mimic of miR-7 as a treatment for cancer.

“This pivotal funding from the MRCF allows Mireven to expand and undertake in vivo studies to examine the delivery of miR-7 with independent parties,” Mireven Chairman Stephen Thompson said in a statement.

Last month, Mireven signed a deal to evaluate Silence Therapeutics' delivery technologies with its miR-7 mimetic (GSN 8/23/2012). It said that it has also inked a second deal with an undisclosed “international company” focused on “positioning miR-7 as a cancer therapeutic.”

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.